Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment.

Cell metabolism·2026
Same author

Monocytes and Macrophage-derived mediators influence the behavior of squamous cell carcinoma cell lines.

Journal of applied oral science : revista FOB·2025
Same author

ONECUT2: a validated drug target and lineage plasticity driver in prostate cancer and other malignancies.

Endocrine-related cancer·2025
Same author

National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Therapeutic targeting of prostate-specific membrane antigen could limit its potential as benchmark imaging.

Nature reviews. Urology·2025
Same author

Noninvasive Assessment of β-Secretase Activity Through Click Chemistry-Mediated Enrichment of Neuronal Extracellular Vesicles to Detect Alzheimer's Disease.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025

Related Experiment Video

Updated: Jun 18, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Pazopanib: therapeutic developments.

Suwicha Limvorasak1, Edwin M Posadas

  • 1University of Chicago, Department of Pharmaceutical Services, IL 60637, USA.

Expert Opinion on Pharmacotherapy
|December 4, 2009
PubMed
Summary

Pazopanib, a VEGF inhibitor, shows efficacy and tolerability in advanced cancer treatment. Its FDA approval highlights its potential alongside other targeted therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Pazopanib is an orally available, potent inhibitor targeting vascular endothelial growth factor (VEGF).
  • VEGF inhibitors are a growing class of targeted cancer therapies with demonstrated clinical efficacy.
  • Pazopanib has undergone advanced clinical development for various advanced cancers.

Purpose of the Study:

  • To review the clinical profile of pazopanib, including its efficacy and toxicity.
  • To compare pazopanib's activity and safety with existing therapeutic agents.
  • To discuss pazopanib's potential role and differentiation among similar targeted therapies.

Main Methods:

  • Review of Phase III clinical trial data for pazopanib in metastatic renal cell carcinoma.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Jun 18, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

  • Analysis of reported efficacy and toxicity profiles.
  • Comparative assessment against approved agents in the same therapeutic class.

    • Main Results:

    • Pazopanib demonstrated clinical efficacy comparable to approved agents in metastatic renal cell carcinoma.
    • The study noted variations in toxicity compared to other treatments.
    • Pazopanib has recently received FDA approval for this indication.

    Conclusions:

    • Pazopanib is a clinically effective and well-tolerated VEGF inhibitor.
    • Its unique toxicity profile may differentiate it from other VEGFR inhibitors.
    • Further evaluation of combinatorial strategies involving pazopanib is warranted.